Market closedNon-fractional
Harvard Bioscience/HBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Harvard Bioscience
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Ticker
HBIO
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Holliston, United States
Employees
404
Website
www.harvardbioscience.com
HBIO Metrics
BasicAdvanced
$145M
Market cap
-
P/E ratio
-$0.20
EPS
1.46
Beta
-
Dividend rate
Price and volume
Market cap
$145M
Beta
1.46
Financial strength
Current ratio
1.875
Quick ratio
0.762
Long term debt to equity
46.344
Total debt to equity
51.75
Interest coverage (TTM)
-0.46%
Management effectiveness
Return on assets (TTM)
-0.69%
Return on equity (TTM)
-12.20%
Valuation
Price to revenue (TTM)
1.341
Price to book
2.14
Price to tangible book (TTM)
-57.28
Price to free cash flow (TTM)
13.243
Growth
Revenue change (TTM)
-6.76%
Earnings per share change (TTM)
306.99%
3-year revenue growth (CAGR)
0.46%
3-year earnings per share growth (CAGR)
26.21%
What the Analysts think about HBIO
Analyst Ratings
Majority rating from 3 analysts.
HBIO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$25M
-12.81%
Net income
-$4.6M
155.56%
Profit margin
-18.77%
193.28%
HBIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.04
$0.01
$0.04
$0.02
-
Expected
$0.06
$0.04
$0.05
$0.02
$0.05
Surprise
-36.84%
-75.00%
-20.00%
-14.28%
-
HBIO News
AllArticlesVideos
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
GlobeNewsWire·2 months ago
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
GlobeNewsWire·2 months ago
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harvard Bioscience stock?
Harvard Bioscience (HBIO) has a market cap of $145M as of July 27, 2024.
What is the P/E ratio for Harvard Bioscience stock?
The price to earnings (P/E) ratio for Harvard Bioscience (HBIO) stock is 0 as of July 27, 2024.
Does Harvard Bioscience stock pay dividends?
No, Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Harvard Bioscience dividend payment date?
Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Harvard Bioscience?
Harvard Bioscience (HBIO) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Harvard Bioscience stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.